Fourth ICMC International Congress, New York 2024

---

PROGRAM

8:15- 8:45
Welcome and Introduction by the Population Council and ICMC
Jim Sailer (Population Council, USA), Regine Sitruk-Ware (Population Council, USA) David Serfaty (ICMC, FR) 

Session 1: NEW FIELDS OF RESEARCH

Chair: Philippe Bouchard (FR), Jim Sailer (USA)

8:45 – 09:30
Selective Retinoic Acid Receptor Alpha Antagonist
Chemistry approach: Gunda Georg (U of Minnesota, USA)
Proof-of Concept in in vivo models: Debra Wolgemuth (Columbia, USA)

09:30 – 10:00
Soluble Adenyl Cyclase (sAC). Progress in development
Jochen Buck (Cornell, USA) & Lonny Levin (Cornell, USA)

10:00 – 10:15 Break

10:15 – 10:40
Update on Male Contraceptive Initiative Activities in progress
Logan Nickels (MCI, USA)

10:40 – 11:00
Clinical development of YCT 529. Inhibitor of retinoic acid receptor-alpha
Akash Bakshi (YourChoice Therapeutics, USA)

Session 2: HORMONAL METHODS

Chair: David Archer (USA), Mitch Creinin (USA)

11:00 – 11:30
NES/T transdermal gel efficacy study
Christina Wang (UCLA, USA)

11:30 – 12:00p
Novel findings: Time to effective sperm suppression in Male Hormonal Contraception
Diana Blithe (NICHD, USA)

12:00p – 12:30p
Novel Androgens for Male Contraception
Stephanie Page (U of Washington, USA)

12:30 – 13:30 Lunch

Session3: BEHAVIORAL ASPECTS OF MALE CONTRACEPTION

Chair: Ronald Swerdloff (USA), Stephanie Page (USA)

13:30 – 14:00
Male Contraception potential impact on Global Reproductive Health
Nancy Kidula (WHO, CH, virtual)

14:00 – 14:30
Demand for male contraceptives: Landscape
Steve Kretschmer (DesireLine, USA)

14:30 – 14:45 (ISA-sponsored Abstract)
Population differences in responses to Male Hormonal Contraception (Lessons Learned from the WHO-CONRAD phase III study)
Michael Zitzmann (U of Münster, DE)

14:45 – 15:00 Break

Session 4: NEW APPROACHES TO MALE CONTRACEPTION

Chair: Richard Anderson (UK), William Bremner (USA), Peter Liu (USA)

15:00 – 15:30
PANEL on Guidelines for Male Contraception Studies
Practice and Development of Male Contraception- EAA-ISA Guidelines
Christina Wang (UCLA, USA), Stanton Honig (Yale, USA), Cristina Meriggiola (U of Bologna, IT), Regine Sitruk-Ware (USA)

15:30 – 16:00
Non-hormonal methods: Landscape
John Amory (U of Washington, USA, virtual)

16:00 – 16:30
Update of ADAM, a vas-occlusive hydrogel device
Kevin Eisenfrats (Contraline, USA)

16:30 – 16:45 (Abstract)
Plan A: Non-Hormonal Vas Occlusion
Charles Carignan (CAIRDAC, USA)

16:45 – 10:00 (Abstract)
A new endocrine approach to oral MC?
Herjan Coelingh Bennink (Pandora Endocrine Innovation, NL)

Session 5: ROLE OF THE COLLABORATIVE AGENCIES

Chair: Kristina Gemzell (SE), Cristina Meriggiola (IT)

17:00 – 17:45
Panel discussion:
Mark Barone (BMGF, USA), Diana Blithe (NICHD, USA), Vera Halpern (FHI360, USA), Nancy Kidula (WHO, CH, virtual), Elaine Lissner (Parsemus, USA), Heather Vahdat (MCI, USA), Jim Sailer (Population Council, USA)

Session 6: GENERAL DISCUSSION

Chairs: Regine Sitruk-Ware (USA/FR), David Serfaty (FR)

17:45 – 18:15
Timeline from Development to Market for male contraceptives, Conclusions
Stephanie Page (U of Washington, USA), Diana Blithe (NICHD, USA)

18:15 – 19:15
Wine and Cheese Cocktail Party

 

Organizing Scientific Committee: Diana Blithe, Philippe Bouchard, Kristina Gemzell-Danielsson, Eberhard Nieschlag, David Serfaty, Regine Sitruk-Ware (Chair), Heather Vahdat, Christina Wang